Chinese Journal of Tissue Engineering Research ›› 2022, Vol. 26 ›› Issue (31): 5053-5061.doi: 10.12307/2022.734

Previous Articles     Next Articles

Gene-modified stem cells therapy for osteoporosis: a meta-analysis of preclinical studies

Xiang Qianru1, Deng Xuejian1, Chen Huafeng1, Liang Jiamin1, An Min1, Yang Li1, 2   

  1. 1Department of Endocrinology and Metabolism, 2Department of Nutrition, Zhujiang Hospital, Southern Medical University, Guangzhou 510220, Guangdong Province, China
  • Received:2021-10-25 Accepted:2021-11-23 Online:2022-11-08 Published:2022-04-25
  • Contact: Yang Li, MD, Master’s supervisor, Associate professor, Associate chief physician, Department of Endocrinology and Metabolism, and Department of Nutrition, Zhujiang Hospital, Southern Medical University, Guangzhou 510220, Guangdong Province, China
  • About author:Xiang Qianru, Master candidate, Department of Endocrinology and Metabolism, Zhujiang Hospital, Southern Medical University, Guangzhou 510220, Guangdong Province, China
  • Supported by:
    the Natural Science Foundation of Guangdong Province, No. 2014A030310036 and No. 2018A030313609 (to YL); Clinical Research Nursery Project of Southern Medical University, No. LC2016YM007 (to YL)

Abstract: OBJECTIVE: Gene-modified stem cells therapy in osteoporosis is a promising method with controversy. This article analyzed the effects of gene-modified stem cells on bone histometrology and calcium phosphorus metabolism in osteoporosis animals by meta-analysis, and evaluated its efficacy compared with simple stem cells.
METHODS: PubMed, MEDLINE, Web of Science, CNKI, and Wanfang databases were used to collect articles about gene-modified stem cells therapy in osteoporosis animals before June, 2021. R4.1.0 software was used for meta-analysis. The primary outcome measures were bone mineral density and trabecular bone volume (BV/TV). The secondary outcome measures were trabecular number (Tb.N), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), blood phosphorus, blood calcium, and blood bone alkaline phosphatase.  
RESULTS: Totally 22 articles of animal experiments were included. The meta-analysis results showed: (1) gene-modified stem cells of the experimental group increased bone mineral density (SMD=2.23, 95%CI:1.34-3.11, P < 0.01), BV/TV (SMD=1.95, 95%CI:1.07-2.83, P < 0.01), Tb.N (SMD=2.33, 95%CI:1.34-3.32, P < 0.01), Tb.Th (SMD=1.47, 95%CI:0.70-2.24, P < 0.01) and blood phosphorus (MD=0.10, 95%CI:0.08-0.12, P=0.08) in simple stem cells of the control group. (2) Tb.Sp (SMD=-2.77, 95%CI:-4.17 to -1.36, P < 0.01), blood calcium (MD=-0.04, 95%CI:-0.06 to -0.03, P=0.82), and blood bone alkaline phosphatase (MD=-4.46, 95%CI:-5.12 to -3.80, P=0.96) of the experimental group were lower than those in the control group.
CONCLUSION: Compared with simple stem cells, positive gene-modified stem cells improve bone mineral density, bone quality, and calcium phosphorus metabolism in osteoporosis. Due to the included literature’s insufficient quality, higher quality and more random control trials are required to supplement the argument.

Key words: stem cells, osteoporosis, genetic modification, meta-analysis, animals, experiment, preclinical studies, bone mineral density

CLC Number: